Codex™

Data Sheet

Codex SARS-CoV-2-XBB.1.16.6 Variant Pseudovirus Particles (SARS-CoV-2-XBB.1.16.6-PP)

Features

- **Robust:** Excellent signal to noise (basal) ratio.
- **Easy to use:** Amenable to HTS format (96-well, 384-well and 1536-well format).

Applications

- Working perfectly for Luc Pseudovirus to get robust signal, screening potential inhibitor to block SARS-CoV-2 XBB.1.16.6 variant entry and viral protein translation

Product Information

Catalog Number:	Components
CB-97200-213-1ml	**1ml SARS-CoV-2-XBB.1.16.6 Variant Pseudovirus Particles**
CB-97200-213-5ml	**5ml SARS-CoV-2- XBB.1.16.6 Variant Pseudovirus Particles**

Storage

Store at -80˚C

ASSAY PROTOCOL

Cell Infection:

1. HEK293-ACE2 cells (CB-97100-203) to be infected and seed ~20K cells per well into 96-well plates (50 μl per well) DMEM with 10% HyClone™ FetalClone™ II Serum (no antibiotics) or 5K cells per well into 384-well plates (15 μl per well)
2. Culture cells overnight to make sure the cells stably adhere to the plates.
3. On the 2nd day, remove media, add 50 μl SARS-CoV-2-XBB.1.16.6-PP into each well (12.5 μl for 384-well plate). Spin at 700 rpm for 15 min at 4°C
   Note: Thaw the PPs quickly with room temperature water
4. Incubate for 2 hr at 37 °C
5. Add 50 μ DMEM with 10% FC into each well (12.5 μl for 384-well plates).
6. Incubate for 42 hr at 37 °C

Measurement of Luciferase Activity in Infected cells

1. Add 100 μl Codex's Luciferase assay reagent (CB-80552-010). (25 μl for 384-well plates).
2. Read in a luminescence plate reader, record the data.

Tel: (240)-632-8810 Fax: (240)-632-8820 E-Mail: orders@codexbiosolutions.com www.codexbiosolutions.com

DATA



Figure 1. Pseudoviral Particle (PP) Infection Assays. SARS-CoV-2-XBB.1.16.6 variant pseudoviral particles on HEK293-ACE2 cells in 384-well format.

Legends: **SARS-CoV-2-XBB.1.16.6-PP**: SARS-CoV-2-XBB.1.16.6 Variant MLV Pseudovirus Particles;
.

Figure 2. Antibody neutralization assays using XBB.1.16.6 pseudoviral particle (PP) infection method.
Each antibody dose-response curve represents the relative infectivity under serial dilutions of antibody. At each Ab concentration, HEK293-ACE2 cells were co-incubated with SARS-CoV-2 XBB.1.16.6 pseudoviral particles in the presence of the antibody.

Tel: (240)-632-8810 Fax: (240)-632-8820 E-Mail: orders@codexbiosolutions.com www.codexbiosolutions.com